What’s Coming Down the Pipeline for Parkinson’s?

If you’ve been wondering whether anything genuinely new is on the horizon for Parkinson’s, IQVIA’s 2025 pipeline report offers a clear and well-researched answer: yes—and it’s not just more of the same. From smarter ways to deliver levodopa, to completely new classes of drugs that target the underlying biology of Parkinson’s, this report is one of the best overviews out there. It doesn’t just talk about molecules in petri dishes—it focuses on therapies that are in late-stage trials, with real potential to reach people in the next few years. We’ve broken it down for you here, in plain English, with all the juicy details. 🚀 Making Dopamine Work Better (Without the Yo-Yo) Many of the newest treatments aim to smooth out the peaks and crashes of current dopamine-based therapy—especially for those experiencing motor fluctuations or long “off” periods. 🔄 ND0612 – Continuous levodopa infusion, no surgery required Instead of popping pills every few hours, ND0612 delivers liquid levodopa/carbidopa continuously through a tiny pump worn on your belt or upper leg. It works a bit like an insulin pump, keeping dopamine levels steady throughout the day. • Who might benefit? People with advanced Parkinson’s who are still responding to levodopa but struggle with “off” time and dyskinesia. • How close is it? Phase III trials are done, and it could be available in the US and Europe by 2026. • Big perk: No need for intestinal surgery (unlike Duodopa). 💊 Tavapadon – A gentler dopamine agonist Tavapadon is a once-daily pill that selectively activates the D1 dopamine receptor. That means it gives you motor symptom relief, but with fewer side effects like hallucinations, sleep attacks, or impulse control issues. • Who might benefit? Early- to mid-stage Parkinson’s patients, especially those who’ve had trouble with other dopamine agonists. • How close is it? Phase III results have been positive. AbbVie, who now own the drug, are aiming for approval soon. • What’s different: More targeted activation, fewer cognitive side effects. 💊 P2B001 – Two old drugs, one smart combo This pill combines extended-release pramipexole (a dopamine agonist) and rasagiline (a MAO-B inhibitor) in a single, once-daily tablet. It’s designed for people with early-stage Parkinson’s who want to delay starting levodopa. • Who might benefit? Newly diagnosed people looking to maintain motor function with fewer pills. • What’s clever: Lower doses of both drugs, fewer side effects, and more stable symptom control. 💉 ABBV-951 (Foscarbidopa/Foslevodopa) – Continuous subcutaneous infusion Think of this as a more advanced version of ND0612. ABBV-951 also delivers levodopa/carbidopa continuously under the skin, helping to maintain stable dopamine levels. The main difference? It uses a phosphate-based version that’s easier to absorb and needs less volume. • Current stage: Already approved and available. ABBV-951, also known as foscarbidopa/foslevodopa and marketed as Vyalev, is approved and available in several countries for the treatment of motor fluctuations in adults with advanced Parkinson's disease. It was approved in Canada in May 2023, in Australia in March 2024, and in the United States in October 2024. It is also available in the UK via the National Health Service since February 2024, • Designed for: People with motor complications who need precise control. 🧬 Not Just Treating Symptoms: Slowing the Disease Itself This is the holy grail—therapies that go beyond masking symptoms and actually target the cause or protect the brain. And for the first time, several are deep into human trials. 🧪 BIIB122/DNL151 – LRRK2 inhibitor This oral therapy blocks a protein called LRRK2, which is overactive in many people with Parkinson’s, especially those with genetic variants. By turning it down, the hope is to reduce inflammation and stop alpha-synuclein from clumping up. • For whom? People with and without LRRK2 mutations. • Why it matters: Could slow the actual progression of the disease. 🧠 UCB0599 (Minzasolmin) – Stops protein clumping This drug aims to prevent alpha-synuclein (the misfolded protein behind Lewy bodies) from clumping in the first place. It doesn’t clear the clumps, but stops them spreading—potentially halting the domino effect that leads to brain cell loss. • Stage: Phase II trials completed, more underway. • Potential benefit: Disease modification. 🧬 KM-819 – A brain cell protector Developed in South Korea, this drug blocks a protein (FAS-associated factor 1) linked to cell death. In theory, it could protect dopamine neurons from degeneration. • Status: In Phase II trials. • Why it’s promising: Could work well with other therapies to keep remaining brain cells alive. 🧬 LBT-3627 – A peptide that calms inflammation This isn’t about dopamine at all—it targets immune cells in the brain called microglia. By calming them down, it may reduce inflammation and slow progression. Think of it as Parkinson’s firefighting from the inside. • Stage: Early trials in the US are underway. 🧠 Thinking Beyond Dopamine: New Approaches for “Off” Time Not everyone responds well to levodopa forever, and some want alternatives. These drugs offer new ways to control symptoms without fiddling with dopamine directly. ⚙️ Solengepras (Cerevance) – Tames the motor circuits Solengepras targets a brain receptor called GPR6, which influences movement without relying on dopamine. In early studies, it reduced “off” time by about 1.6 hours per day. • Why it’s exciting: Works on a completely different pathway—could be added to your current meds. • Status: Phase III development. 💡 UCB0022 – Activates dopamine only when needed Still in early trials, this clever compound activates dopamine D1 receptors only in low dopamine conditions. That means it gives you relief when you need it—without constant overstimulation. • Who it might help: Those sensitive to dopamine-related side effects. • Bonus: Could reduce dyskinesia risk. 🧪 Still Experimental… But Ones to Watch These are the early-stage contenders — treatments in Phase I or just entering Phase II. They’re not as close to approval as others, but they offer new ideas, fresh mechanisms, and potential future breakthroughs. 🧬 Lu AF28996 – Targeting both D1 and D2 dopamine receptors This oral drug from Lundbeck is designed to stimulate both D1 and D2 receptors, potentially improving motor symptoms while balancing out side effects. It’s one of the few drugs exploring this dual-target strategy. • Stage: Early clinical trials (Phase I). • Why it matters: Could offer more natural dopamine replacement and better “on” time. 🧠 NLRP3 inhibitors – Tackling brain inflammation A few companies (including Inflazome and Roche) are working on drugs that block NLRP3, a protein linked to inflammation in the brain. In Parkinson’s, chronic inflammation is thought to accelerate disease progression—so calming it down could be protective. • Still preclinical or Phase I. • Potential bonus: Could help with cognitive symptoms as well as motor ones. 🧬 Stem cell therapies – Replacing lost neurons Several academic groups and biotech firms (like BlueRock and Aspen Neuroscience) are experimenting with transplanting dopamine-producing neurons derived from stem cells directly into the brain. The dream? To replace what’s been lost. • Very early trials underway in Japan, US, and Europe. • Challenges: Safety, immune rejection, long-term survival. 🧪 Gene therapy – Rewriting the disease Gene therapy is making quiet progress too. One example: Voyager Therapeutics is developing a treatment that delivers a gene to help the brain make its own dopamine, using an injection directly into the brain. • Early-phase trials show it’s possible, but delivery is complex. • Potential: One-time treatment that rewires the dopamine pathway from the inside. 🧠 The Bottom Line There’s no magic bullet—yet. But for the first time in decades, the Parkinson’s pipeline is full of real contenders, not just tweaks. We’re seeing: • More refined dopamine therapies with fewer side effects. • Smarter delivery systems (like pumps you can wear, no surgery needed). • Truly new mechanisms—from protein clump blockers to immune system modulators. • And even early shots at disease-modifying treatments. Whether you’ve just been diagnosed or have lived with Parkinson’s for years, the next few years could bring options that offer more stability, fewer side effects, and—most excitingly—hope that we’re inching closer to slowing this disease.